Root, Inc. Class A Common Stock (ROOT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
This Small-Cap Growth Stock Has Surged 600% in 2024 and Its Recent Results Shocked Investors. Is the Stock a Buy Today?
This small-cap stock has skyrocketed after posting a surprising profit in the third quarter.
Root, Inc. (ROOT) Hit a 52 Week High, Can the Run Continue?
Root (ROOT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Root, Inc. Has Entered The World Of Profits (Rating Upgrade)
Root, Inc. has finally achieved its first profitable quarter, reducing the risks and providing a better basis for valuation. Following wild price fluctuation after ROOT's earnings release, the closing price fell to a fair range for no growth and a bargain if growth materializes. Auto insurance remains competitive, however, and bigger competitors may yet test Root's ability to capture market share from its small starting point.
3 Insurance Stocks Making Moves After Earnings
Shares of insurance name Root (ROOT) are trading at roughly three-year highs , on track for their best session on record after a surprise third-quarter earnings beat.
Insurance Stock Eyes Best Day Ever After Earnings
Shares of Root Inc (NASDAQ:ROOT) are skyrocketing to nearly three-year highs, after the auto insurance name posted surprise third-quarter profits of $1.35 per share.
Root, Inc. (ROOT) Q3 2024 Earnings Call Transcript
Root, Inc. (NASDAQ:ROOT ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Matt LaMalva - Head, Investor Relations Alex Timm - Co-Founder & Chief Executive Officer Megan Binkley - Chief Financial Officer Conference Call Participants Tommy McJoynt - KBW Yaron Kinar - Jefferies Operator Ladies and gentlemen greetings and welcome to the Root Inc. 3Q 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Root, Inc. (ROOT) Q3 Earnings and Revenues Surpass Estimates
Root, Inc. (ROOT) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of a loss of $0.61 per share. This compares to loss of $3.16 per share a year ago.
Root Inc. Q3 Earnings Preview: Loss Ratio Not Sustainable
Root, Inc. will announce Q3 2024 earnings post-market on October 30th. I do not believe the market is fairly valuing the impact of scaling and competition on Root's ability to drive margin. While there is upside potential if everything goes right, fundamental industry challenges will continue to constrain growth.
Undercovered Dozen: Root, Marqeta, Caesars Entertainment, Rumble, Pubmatic +
In this article, we share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Ideas this week include two new publicly traded notes, a satellite company, a card-issuer and processor, a PC insurance company, and more. One article highlighted is analyst Jussi Askola's current "favorite dividend pick".
Root, Inc. (ROOT) Reports Q2 Loss, Tops Revenue Estimates
Root, Inc. (ROOT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $2.55 per share a year ago.
Root, Inc. (ROOT) Q2 2024 Earnings Call Transcript
Root, Inc. (NASDAQ:ROOT ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Matt LaMalva - Head, IR Alex Timm - Co-Founder & CEO Megan Binkley - CFO Conference Call Participants Tommy McJoynt - KBW Yaron Kinar - Jefferies Elyse Greenspan - Wells Fargo Michael Ward - Citi Operator Greetings, and welcome to Root, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way
Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.
